Hyperliquid Strategies Inc (PURR)

$8.05 -0.16 (-1.95%)
Market Cap 1.16B
Revenue (ttm) 1.00M
Net Income (ttm) -16.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 3.91
Profit Margin -1,601.00%
Debt to Equity Ratio 0.00
Volume 11,961,301
Avg Vol 14,807,504
Day's Range N/A - N/A
Shares Out 144.45M
Stochastic %K 26%
Beta 1.66
Analysts Strong Sell
Price Target $13.05

Company Profile

Hyperliquid Strategies Inc. operates as a digital asset treasury company focused on the blockchain and cryptocurrency sector. The company provides investors exposure to the HYPE token through treasury management strategies, such as token accumulation, staking, and yield optimization within the Hyperliquid ecosystem. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets
Sector: Financial Services
Phone: 212-883-4330
Address:
477 Madison Avenue, 22nd Floor, New York, United States
anderbear
anderbear Jul. 4 at 4:19 PM
$ADA.X is shitcoin. Buy $PURR and native token $HYPE.X ... real value, they are making real money with hyperliquid. Thank me later !
0 · Reply
Donald_Kerabatsos
Donald_Kerabatsos Jul. 4 at 5:44 AM
$HYPE.X $PURR https://x.com/RyanWatkins_/status/2073144432879079719?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
0 · Reply
FullTiltDayTrader
FullTiltDayTrader Jul. 3 at 10:05 PM
$PURR
0 · Reply
stonedbunny
stonedbunny Jul. 3 at 6:40 PM
$8.56 on $PURR
0 · Reply
Tetoooo
Tetoooo Jul. 3 at 5:56 PM
$PURR AI of FinPile said it has bad fundamentals
0 · Reply
Avocado_smash
Avocado_smash Jul. 3 at 5:54 PM
$PURR This look like found the support and might swinging up, but: each day can be gap up and selling from the top red candle. funny right
0 · Reply
SpaceFarce
SpaceFarce Jul. 3 at 5:41 PM
$PURR 10 Monday
0 · Reply
anderbear
anderbear Jul. 3 at 5:40 PM
$PURR buying.. kill useless $ETH.X
0 · Reply
goalseeker
goalseeker Jul. 3 at 5:27 PM
$PURR MONday ?? well if $HYPE hits $80 ,, purr $12?
0 · Reply
Donald_Kerabatsos
Donald_Kerabatsos Jul. 3 at 4:58 PM
$PURR
0 · Reply
Latest News on PURR
Hyperliquid Strategies management to meet with Oppenheimer

2026-07-01T19:50:11.000Z - 2 days ago

Hyperliquid Strategies management to meet with Oppenheimer

Hyperliquid Strategies to be added to Russell 3000, 2000, S&P Global BMI Indices

2026-06-29T20:20:21.000Z - 4 days ago

Hyperliquid Strategies to be added to Russell 3000, 2000, S&P Global BMI Indices

Hyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI Indices

Jun 29, 2026, 4:15 PM EDT - 4 days ago

Hyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI Indices

Hyperliquid Strategies Registration statement: Registration filing

Jun 25, 2026, 8:00 AM EDT - 9 days ago

Hyperliquid Strategies Registration statement: Registration filing

Hyperliquid Strategies Inc Relaunches Website with Expanded Analytics, HYPE Tokenomics and Insights Sections

Jun 16, 2026, 9:00 AM EDT - 18 days ago

Hyperliquid Strategies Inc Relaunches Website with Expanded Analytics, HYPE Tokenomics and Insights Sections

Hyperliquid Strategies Registration statement: Registration filing

Jun 16, 2026, 8:00 AM EDT - 18 days ago

Hyperliquid Strategies Registration statement: Registration filing

Hyperliquid Strategies CEO on why he thinks banks are undervaluing SpaceX's IPO

Jun 4, 2026, 5:46 PM EDT - 4 weeks ago

Hyperliquid Strategies CEO on why he thinks banks are undervaluing SpaceX's IPO

SPCX

Crypto ETFs: From Bitcoin to Hyperliquid

May 28, 2026, 7:58 AM EDT - 5 weeks ago

Crypto ETFs: From Bitcoin to Hyperliquid

BHYP FBTC IBIT MSBT MSTR THYP TXXH

Hyperliquid Strategies Registration statement: Registration filing

May 22, 2026, 8:00 AM EDT - 6 weeks ago

Hyperliquid Strategies Registration statement: Registration filing

Hyperliquid Strategies files to sell 35.16M shares of common stock for holders

2026-05-22T10:05:07.000Z - 6 weeks ago

Hyperliquid Strategies files to sell 35.16M shares of common stock for holders

Hyperliquid Strategies price target raised to $8 from $6 at Cantor Fitzgerald

2026-05-11T12:53:34.000Z - 7 weeks ago

Hyperliquid Strategies price target raised to $8 from $6 at Cantor Fitzgerald

Hyperliquid Strategies Earnings Call Transcript: Q3 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Hyperliquid Strategies Earnings Call Transcript: Q3 2026

Hyperliquid Strategies Slides: Q3 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Hyperliquid Strategies Slides: Q3 2026

Hyperliquid Strategies Quarterly report: Q3 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Hyperliquid Strategies Quarterly report: Q3 2026

Hyperliquid Strategies Earnings release: Q3 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Hyperliquid Strategies Earnings release: Q3 2026

Hyperliquid Strategies, Unit Labs announce validator on Hyperliquid

2026-05-07T20:47:48.000Z - 2 months ago

Hyperliquid Strategies, Unit Labs announce validator on Hyperliquid

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

May 7, 2026, 4:15 PM EDT - 2 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

Hyperliquid Strategies and Unit Labs Announce Validator on Hyperliquid

May 7, 2026, 4:15 PM EDT - 2 months ago

Hyperliquid Strategies and Unit Labs Announce Validator on Hyperliquid

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026

Apr 28, 2026, 4:15 PM EDT - 2 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026

Hyperliquid Strategies initiated with a Buy at Maxim

2026-04-24T12:14:26.000Z - 2 months ago

Hyperliquid Strategies initiated with a Buy at Maxim

Hyperliquid Strategies initiated with a Buy at Maxim

2026-04-24T12:06:12.000Z - 2 months ago

Hyperliquid Strategies initiated with a Buy at Maxim

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

Mar 24, 2026, 4:15 PM EDT - 3 months ago

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

Hyperliquid Strategies Slides: Corporate presentation

Feb 16, 2026, 7:00 AM EST - 4 months ago

Hyperliquid Strategies Slides: Corporate presentation

Hyperliquid Strategies Earnings Call Transcript: Q2 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Hyperliquid Strategies Earnings Call Transcript: Q2 2026

Hyperliquid Strategies Quarterly report: Q2 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Hyperliquid Strategies Quarterly report: Q2 2026

Hyperliquid Strategies Earnings release: Q2 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Hyperliquid Strategies Earnings release: Q2 2026

Hyperliquid Strategies Slides: Q2 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Hyperliquid Strategies Slides: Q2 2026

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 11, 2026, 6:45 AM EST - 5 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 5 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 8, 2025, 9:20 AM EST - 7 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 3, 2025, 5:45 PM EST - 7 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Dec 2, 2025, 4:30 PM EST - 7 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Nov 18, 2025, 9:00 AM EST - 8 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Hyperliquid Strategies Slides: Investor presentation

Nov 12, 2025, 7:00 AM EST - 8 months ago

Hyperliquid Strategies Slides: Investor presentation

Hyperliquid Strategies Registration statement: Registration Filing

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Hyperliquid Strategies Registration statement: Registration Filing

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Oct 15, 2025, 10:03 AM EDT - 9 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Sep 19, 2025, 9:00 AM EDT - 10 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 11, 2025, 9:15 AM EDT - 11 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Aug 4, 2025, 8:40 AM EDT - 11 months ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

Jul 14, 2025, 6:00 AM EDT - 1 year ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

May 1, 2025, 9:00 AM EDT - 1 year ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 4, 2025, 9:00 AM EDT - 1 year ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 4:15 PM EDT - 1 year ago

Sonnet Announces Release of Corporate Update Video

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 26, 2025, 9:05 AM EDT - 1 year ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

anderbear
anderbear Jul. 4 at 4:19 PM
$ADA.X is shitcoin. Buy $PURR and native token $HYPE.X ... real value, they are making real money with hyperliquid. Thank me later !
0 · Reply
Donald_Kerabatsos
Donald_Kerabatsos Jul. 4 at 5:44 AM
$HYPE.X $PURR https://x.com/RyanWatkins_/status/2073144432879079719?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
0 · Reply
FullTiltDayTrader
FullTiltDayTrader Jul. 3 at 10:05 PM
$PURR
0 · Reply
stonedbunny
stonedbunny Jul. 3 at 6:40 PM
$8.56 on $PURR
0 · Reply
Tetoooo
Tetoooo Jul. 3 at 5:56 PM
$PURR AI of FinPile said it has bad fundamentals
0 · Reply
Avocado_smash
Avocado_smash Jul. 3 at 5:54 PM
$PURR This look like found the support and might swinging up, but: each day can be gap up and selling from the top red candle. funny right
0 · Reply
SpaceFarce
SpaceFarce Jul. 3 at 5:41 PM
$PURR 10 Monday
0 · Reply
anderbear
anderbear Jul. 3 at 5:40 PM
$PURR buying.. kill useless $ETH.X
0 · Reply
goalseeker
goalseeker Jul. 3 at 5:27 PM
$PURR MONday ?? well if $HYPE hits $80 ,, purr $12?
0 · Reply
Donald_Kerabatsos
Donald_Kerabatsos Jul. 3 at 4:58 PM
$PURR
0 · Reply
Dirtdemon75
Dirtdemon75 Jul. 3 at 4:56 PM
$PURR
0 · Reply
Lastshare
Lastshare Jul. 3 at 4:54 PM
$PURR Monday, funday!
0 · Reply
ACCool
ACCool Jul. 3 at 4:34 PM
$HYPE.X $PURR interesting
0 · Reply
Dirtdemon75
Dirtdemon75 Jul. 3 at 4:30 PM
$PURR
0 · Reply
Dannyu
Dannyu Jul. 3 at 3:44 PM
$PURR hype up 7%….so $PURR down 3%….isnt that how it works lately?😂
0 · Reply
FleeceWood_Mac
FleeceWood_Mac Jul. 3 at 2:15 PM
$PURR this is going to fly come Monday. $HYPE.X is the truth
0 · Reply
24_7Markets
24_7Markets Jul. 3 at 12:11 PM
$PURR NFA I guess is the proper term. Not Financial Advice
0 · Reply
24_7Markets
24_7Markets Jul. 3 at 12:11 PM
$PURR $HYPE.X To anybody who follows me: Buy all of the $PURR that you can under 10. When $PURR is trading at 50 plus which it will, you will regret not buying in single digits. Cantor's 19 PT is short term. Long term this is 💯 plus like $MSTR. Degenerate advice, NOT NFA
1 · Reply
24_7Markets
24_7Markets Jul. 3 at 10:57 AM
$PURR $HYPE.X Multiple to NAV .96X will change for the better. 100 by the end of August is the word. $BHYP $HYPG for the institutions
1 · Reply
Donald_Kerabatsos
Donald_Kerabatsos Jul. 3 at 3:37 AM
$HYPE.X $PURR https://www.cryptopolitan.com/tradingview-adds-hyperliquid-and-tradexyz-data-feeds-opening-on-chain-markets-to-millions-of-chartists/
0 · Reply
Donald_Kerabatsos
Donald_Kerabatsos Jul. 3 at 3:20 AM
$HYPE.X $PURR https://x.com/RyanWatkins_/status/2072732091494576195?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
0 · Reply
TonyG6ix
TonyG6ix Jul. 3 at 2:07 AM
$PURR skated by on a few eight dollar short puts. Holding a few more.
0 · Reply